Arrhythmogenic cardiomyopathy with left ventricular involvement versus ischemic heart disease: lessons learned from the family study and the reviewed autopsy of a young male

Pilar Molina, Jorge Sanz-Sánchez, Manuel Fenollosa, Marina Martinez-Matilla, Juan Giner and Esther Zorio

Introduction

Sudden cardiac death (SCD) is the leading cause of unexpected natural sudden deaths in developed countries [1, 2] accounting worldwide for 4.5 million cases each year [3]. Among cardiac causes, ischemic heart disease (IHD) is the most frequent cardiac condition causing SCD [1, 2]. The Association of European Cardiovascular Pathology (AECVP), aware about the potential value of a thorou gh postmortem investigation to determine the precise cause of the death, has released updated guidelines to be followed in this scenario [4, 5]. In them, the cause of death can be established as IHD for certain when an acute myocardial infarction is observed at the macroscopic and histological heart examination and with a high probability when only chronic IHD with ischemic scar and/or an atherosclerotic plaque causing at least 75% of lumen reduction are observed [5].

Arrhythmogenic cardiomyopathy (AC) is an inherited rare disease characterized by a progressive myocardial fibrofatty replacement [6]. A growing list of genes is now associated with this condition (Table 1). Mutations in the five desmosomal genes (PKP2, DSG2, DSP, DSC2 and JUP) were identified in affected individuals [7–9]. As in other cardiomyopathies, the penetrance can be incomplete and its clinical expressivity variable among mutation carriers [6]. Its clinical diagnosis is not straightforward, instead a set of major and (or) minor criteria...
confirm the diagnosis [10]. Ventricular arrhythmias (comprising electrical, arrhythmic, structural, histological and familial/genetic items) need to be met to comprise LV involvement. Modified from refs. [7] and [8] with permission.

Table 1. Genetic background of arrhythmogenic cardiomyopathy including the probability of LV involvement. Modified from refs. [7] and [8] with permission.

| Gene     | Protein                  | Estimated % of cases | Inheritance | Expected LV involvement |
|----------|--------------------------|----------------------|-------------|-------------------------|
| CDH2     | N-Cadherin-2             | <2%                  | AD          | –                       |
| CTNNA3   | AlphaT-catenin           | <2%                  | AD          | –                       |
| DES      | Desmin                   | <2%                  | AD          | Frequent and often isolated |
| DSC2     | Desmocollin-2            | 1%–8%                | AD          | If present, associated to RV involvement |
| DSG2     | Desmoglein-2             | 3%–20%               | AD/AR       | Isolated or associated to RV involvement |
| DSP      | Desmoplakin              | 3%–15%               | AD/AR       | Frequent either isolated or associated to RV involvement |
| FLNC     | Filamin C                | <2%                  | AD          | Frequent and usually isolated (also a dilated biventricular cardiomyopathy phenotype can be present) |
| JUP      | Plakoglobin              | <1%                  | AD/AR       | If present, associated to RV involvement |
| LMNA     | Lamin A/C                | <4%                  | AD          | If present, associated to RV involvement |
| PKP2     | Plakophilin-2            | 20%–46%              | AD/AR       | If present, associated to RV involvement |
| PLN      | Phospholamban            | <1%                  | AD          | Frequent and often isolated |
| SCN5A    | Sodium channel           | 2%                   | AD          | If present, associated to RV involvement |
| TGFβ3    | Transforming growth factor β3 | <2%             | AD          | –                       |
| TMEM43   | Transmembrane protein 43 | <2%                  | AD          | If present, associated to RV involvement |
| TTN      | Tritin                   | <10%                 | AD          | –                       |

AD: autosomal dominant; AR: autosomal recessive; LV: left ventricular; RV: right ventricular.

AC was first described in patients with a clear profound right ventricular (RV) structural changes with or without left ventricular (LV) involvement [6]. Since 2008 also left dominant AC (LDAC) forms have been identified [11–14] and certain genes have been more often associated to them (Table 1).

From a histologic perspective, structural changes associated to IHD and AC may include fibrosis, fatty infiltration and myocardial loss, but certain of their characteristics and several additional features may help to distinguish both entities (Table 2).

Herein, we present a case of SCD due to LDAC which was initially misdiagnosed as IHD almost 1 decade ago, exactly when the LDAC forms were just starting to be recognized in the international literature. The review of the case upon the new knowledge recently accumulated reclassified the cause of the death to LDAC. The subsequent thorough family study not only diagnosed more individuals and allowed a tailored management, but also reassured others as healthy relatives. We highlight the importance of critical re-evaluation of previous postmortem reports since fortunately science keeps on moving and some previous diagnoses may not be accurate nowadays. When new diagnoses involve genetic conditions the beneficial effect of reclassifying those cases is crucial for at-risk relatives.

Material and methods

Autopsies were performed at the Instituto de Medicina Legal y Ciencias Forenses de Valencia, Spain. Sudden death was defined as a natural death occurring within 1 h from the onset of symptoms in someone without a known severe condition which could explain such an abrupt outcome (in unpublished cases, the victim should have been checked to be in good health 24 h before death) [15, 16]. When a sudden death was assumed to be caused by a cardiac disease with a certain or a high probability, the death was classified as SCD. IHD-SCD was considered when at least one of the following criteria were present: an atheromatous stenosis >75% in at least one epicardial coronary artery, a complicated plaque (ruptured or eroded with or without thrombosis) and the presence of acute or healed myocardial infarction. AC postmortem diagnosis (at the reviewed autopsy) relied upon the finding of fibrofatty myocardial replacement with myocardial degeneration, as previously described. The macroscopic and histologic study included in the postmortem conformed the available guidelines at that moment [5, 6]. Hematoxylin-eosin and Masson trichrome stainings were examined in formalin-fixed paraffin-embedded myocardial blocks. The macroscopic work-up in his first-degree relatives initially comprised an electrocardiogram (ECG) and an echocardiogram. Their extended cardiological evaluation 9 years later also included a cardiac magnetic resonance (CMR), an ECG-monitoring, and an exercise testing. A comprehensive genetic study with next generation sequencing (NGS) technology and
Table 2. Pitfalls for the differential diagnosis of IHD and AC as the cause of death in postmortem of SCD victims. Put together by the authors, partially based upon refs. [5,6,12–14].

| Cardiac condition | IHD                          | AC                                      |
|-------------------|------------------------------|-----------------------------------------|
| LV fibrosis       | Scars represent the sequelae of previous myocardial infarction. Replacement fibrosis at the scars usually involving the ventricular wall from subendocardium to the subepicardium (can be transmural). The scar coincides with an anatomical coronary distribution (sometimes several territories can be simultaneously affected). | Replacement with or without interstitial fibrosis involving the ventricular wall from subepicardium to the subendocardium (can be only mid-myocardial or transmural). The scar typically affects the inferolateral wall, and sometimes extends to adjacent walls being occasionally completely circumferential. |
| LV fatty infiltration | Fatty infiltration is possible at the myocardial scars of old myocardial infarctions. | Fatty infiltration associates fibrosis and very often degenerated myocytes exhibit cytoplasmic lipid droplets. Lymphocyte infiltrates (ranging from scarce to definite myocarditis) can be present. |
| Other features at the myocardium | Infrequently histological signs of acute or subacute myocardial infarction are identified when the ischemic insult precedes more than 4 h the development of the lethal ventricular arrhythmia causing the death (intramyocardial oedema, haemorrhage and neutrophilic infiltrates). RV is often preserved. Hypertensive heart disease with myocardial remodelling and intramyocardial small vessel disease are frequent. | In rare forms (autosomal recessive) woolly curly hair and keratosis palmoplantaris are extracardiac hallmarks of the disease. Wide variety of ages ranging from adolescents to middle aged, more men than women and often sports-triggered deaths. Familial aggregation is often present. |
| Non-myocardial features | Atherosclerotic plaques are often identified, not always causing significant stenosis (>75%). Infrequently complicated plaques (eroded, ruptured, with or without thrombus) are identified. More frequent over 35 years and typically men with metabolic syndrome features (e.g. non-alcoholic fatty liver disease). Familial aggregation may be present. | In rare forms (autosomal recessive) woolly curly hair and keratosis palmoplantaris are extracardiac hallmarks of the disease. Wide variety of ages ranging from adolescents to middle aged, more men than women and often sports-triggered deaths. Familial aggregation is often present. |

IHD: ischemic heart disease; AC: arrhythmogenic cardiomyopathy; SCD: sudden cardiac death; LV: left ventricular; RV: right ventricular.

copy variation number analyses (including 214 genes associated with inherited cardiac diseases) was performed in an affected individual with a typical LDAC phenotype, a proband’s distant relative. Once the desmoplakin rearrangement was identified in that sample, a predictive genetic testing was offered to the relatives in a cascade cardiogenetic fashion by means of a multiplex ligation-dependent probe amplification (MLPA) of the exons of the desmoplakin gene involved in the mutation. The pedigree was expanded accordingly and an extended cardiological work-up (ECG holter, exercise testing and CMR) was offered only to mutation carriers.

Results

In 2008, an apparently healthy 37-year-old man died suddenly while playing basketball. The postmortem study was performed showing 75% stenosis of the left main and circumflex coronary arteries (Figure 1). Additionally, a significant amount of fatty tissue wrapped the whole heart and a band-like area of subepicardial fibrofatty infiltration with mild myocardial degeneration was identified in LV free wall corresponding to the anterior, lateral and inferior walls (Figure 2). At that point, these findings were assumed to reflect a past myocardial infarction in an adipositas cordis (as an anatomical variant of the normal heart), since also significant coronary stenoses had been clearly identified. His two sisters (the only living first-degree relatives) were offered a cardiological evaluation. They referred that their mother suffered from postpartum dilated cardiomyopathy (DCM) since she was 33 and died at age 54 due to several complications, while their father died at age 60 without any cardiomyopathy. Additionally, the maternal grandfather and several uncles suffered from heart diseases at advanced ages, and no heart transplantation or SCDs (except the proband’s) had occurred in the family. The two sisters were asymptomatic, exhibited no cardiovascular risk factors and their ECGs and echocardiograms remained within normal limits, thus they were discharged. Nine years thereafter, distant relatives from the maternal side of the proband’s family were clinically diagnosed with LDAC and confirmed with the identification of a radical mutation, namely a desmoplakin rearrangement. The proband’s two sisters were then re-evaluated and one of them, now symptomatic with palpitations, was found to
have frequent ventricular ectopies with runs of non-sustained ventricular tachycardias without any structural involvement at the heart imaging (echocardiogram and CMR). The postmortem of the proband was then reviewed and reclassified as LDAC (based on the LV fibrofatty infiltration) with co-occurring significant and stable atherosclerotic coronary stenoses. RV AC involvement was ruled out since only a mild amount of fatty tissue was observed, without myocardial degeneration or replacement fibrosis (Figure 2(D)). Both the proband and his sister with ventricular arrhythmias were mutation carriers. The family study (Table 3, Figure 3) was completed stepwise yielding a total of 19 people studied, including one SCD due to LDAC and mutation carrier (the proband), three living patients diagnosed with LDAC and mutation carriers (two of them with a defibrillator), one mutation carrier with electrical but no structural involvement (one proband’s sister) and 14 healthy relatives not mutation carriers and with normal basic cardiological study (who were discharged).

**Discussion**

Johann Wolfgang von Goethe (1749–1832) once underlined the need to know in order to be able to recognize things (We only see what we know). Likewise in Medicine, only the awareness of a certain disease can open our eyes to recognize and diagnose it. Research moves forward the current knowledge of the illnesses, and their diagnostic criteria and tools change, so that sometimes diagnoses can change when new clues are depicted and diagnoses reconsidered. The high prevalence of IHD as

![Figure 2](image)

**Figure 2.** Macroscopic and histological study of proband’s heart. (A) Cross section of the heart near apex and the immediately above segment. Marked epicardial adipose infiltration with a thick subepicardial band at the left ventricle (LV). Microscopic images of the posterior (B) and lateral (C) wall of the LV that show subepicardial fibrofatty infiltration with different amounts of fibrosis. (D) Right ventricle (RV) showing mild lipomatosis in the external third myocardium, without myocardial degeneration or replacement fibrosis. (E) Detail of the myocyte degeneration.

| Clinical management | TFC 2010 or clinical data if TFC not available | More distant relatives mutation carriers (n = 3) | Obliged mutation carriers (n = 4) |
|---------------------|-----------------------------------------------|-----------------------------------------------|----------------------------------|
| Woman with borderline AC at 42 years old, normal CMR. | Man with definitive AC (LDAC) since 21 years old with severe LV LGE. Woman with definitive AC (LDAC) since 19 years old with severe LV LGE. Woman with possible AC at 63 years old with mild LV LGE. | Woman with DCM since her first pregnancy at 33 years old, dead at 54 years old. Man with cardiomyopathy, dead at 70 years old. Man with no history of heart disease, dead at 48 years old. Woman with no history of heart disease, SCD at 61 years old. | |
| β-blockers, regular follow-up, cascade screening extended to her offspring. | β-blockers, heart failure optimal medical treatment, two ICDs, regular follow-up, genetic counselling for future pregnancies. | | |

TFC 2010: Task Force Criteria released in 2010; AC: arrhythmogenic cardiomyopathy; CMR: cardiac magnetic resonance; LDAC: left ventricular dominant arrhythmogenic cardiomyopathy; LV: left ventricle; LGE: late gadolinium enhancement; DCM: dilated cardiomyopathy; ICD: implanted cardioverter-defibrillator; SCD: sudden cardiac death.
the leading cause of SCD and the scarce (if any) published data concerning LDAC forms in 2008 prompted an inaccurate first diagnosis in the initial postmortem report of our proband. As a result of that, no genetic study was initially performed and the proband’s two sisters were discharged at a young age. Remarkably, these two decisions would not have been made in case of a solid diagnosis of AC in the proband [17, 18]. However, the family-based study performed in other relatives led us again to this family 9 years afterwards, once the LDAC forms had been widely recognized in the international literature and the diagnostic criteria for AC had been changed to include at least one feature (ventricular repolarization) of LV involvement [10]. Fortunately, we were able to complete the studies previously done so that the deceased proband was finally diagnosed of LDAC, one sister was identified as mutation carrier with need of indefinite cardiological reassessment and cascade cardiogenetic study was comprehensively expanded. Of note, we could prove that the proband’s mother had been an obligate mutation carrier and the referred history of postpartum cardiomyopathy presumably corresponded to an advanced biventricular AC form. The desmoplakin radical mutation showed a good co-segregation with the AC phenotype in the whole family and tied in with the LV involvement without or with mild structural disease at the right ventricle (Tables 1 and 2). The finding of genetic rearrangements in AC-related genes is not common. Actually, 160 mutation negative AC patients underwent MLPA studies and 11 (6.9%) were found to harbour this type of genetic mutation often in the PKP2 gene (nine individuals) and rarely in the DSG2 or DSC2 genes (one DSG2 deletion and one DSG2 and DSC2 simultaneous deletion) [19]. No genetic rearrangement in the DSP gene has been published so far.

**Conclusion**

In summary, differential diagnoses are sometimes difficult in Medicine and may vary over time according with scientific endeavours. At a histological level, LV myocardial scars and fatty infiltration may be identified both in IHD and in AC though their distribution and additional features are helpful to distinguish both entities. At a family level, an IHD or an AC diagnosis has profound implications for defining further follow-up, genetic studies and counselling in at-risk relatives. Importantly, correct early diagnoses may help to prevent more SCD in the family.

**Authors’ contributions**

Manuel Fenollosa and Juan Giner performed the macroscopic study of the proband’s autopsy and Pilar Molina performed the histologic study. Jorge Sanz-Sánchez and
Esther Zorio performed the cardiological study of the living relatives. Marina Martínez-Matilla performed the genetic studies. Pilar Molina and Esther Zorio elaborated this manuscript and all the authors approved the final version.

**Compliance of ethical standards**

This study protocol conforms to the ethical guidelines of the 1975 Declaration of Helsinki. All patients gave their informed consent for their study and on behalf of the deceased proband, whose biological samples had been obtained within the protocol of the legal autopsy following the Spanish Laws.

**Disclosure statement**

No potential conflict of interest was reported by the authors.

**Funding**

This work was supported by grants from the Ministerio de Economía y Competitividad [grant number DPI2015-70821-R], Instituto de Salud Carlos III and FEDER Union Europea. Una forma de hacer Europa [grant numbers RD12/0042/0029, PI14/01477 and PI18/01582] and La Fe Biobank [grant number PT17/0015/0043].

**ORCID**

Pilar Molina
http://orcid.org/0000-0003-0968-1992

Esther Zorio
http://orcid.org/0000-0003-3608-4210

**References**

[1] Tseng ZH, Olgin JE, Vittinghoff E, et al. Prospective countywide surveillance and autopsy characterization of sudden cardiac death: POST SCD study. Circulation. 2018;137:2689–2700.

[2] Subirana MT, Juan-Babot JO, Puig T, et al. Specific characteristics of sudden death in a mediterranean Spanish population. Am J Cardiol. 2011;107:622–627.

[3] Mendis S, Puska P, Norrving B. Global Atlas on cardiovascular disease prevention and control. Geneva: WHO; 2011.

[4] Basso C, Burke M, Fornes P, et al. Guidelines for autopsy investigation of sudden cardiac death. Virchows Arch. 2008;452:11–18.

[5] Basso C, Aguilera B, Banner J, et al. Guidelines for autopsy investigation of sudden cardiac death: 2017 update from the Association for European Cardiovascular Pathology. Virchows Arch. 2017;471:691–705.

[6] Basso C, Pilichou K, Bauce B, et al. Diagnostic criteria, genetics, and molecular basis of arrhythmogenic cardiomyopathy. Heart Fail Clin. 2018;14:201–213.

[7] Campuzano O, Alcalde M, Allegue C, et al. Genetics of arrhythmogenic right ventricular cardiomyopathy. J Med Genet. 2013;50:280–289.

[8] Wang W, James CA, Calkins H. Diagnostic and therapeutic strategies for arrhythmogenic right ventricular dysplasia/cardiomyopathy patient. EP Europeace. 2019;21:9–21.

[9] Ortiz-Genga MF, Cuenca S, Dal Ferro M, et al. Truncating FLNC mutations are associated with high-risk dilated and arrhythmogenic cardiomyopathies. J Am Coll Cardiol. 2016;68:2440–2451.

[10] Marcus FI, McKenna WJ, Sherrill D, et al. Diagnosis of arrhythmogenic right ventricular cardiomyopathy/dysplasia: proposed modification of the task force criteria. Eur Heart J. 2010;31:806–814.

[11] Gallo P, d’Amati G, Pelliccia F. Pathologic evidence of extensive left ventricular involvement in arrhythmogenic right ventricular cardiomyopathy. Hum Pathol. 1992;23:948–952.

[12] Sen-Chowdhry S, Syrris P, Prasad SK, et al. Left-dominant arrhythmogenic cardiomyopathy: an under-recognized clinical entity. J Am Coll Cardiol. 2008;52:2175–2187.

[13] Navarro-Manchón J, Fernández E, Igual B, et al. Left dominant arrhythmogenic cardiomyopathy caused by a novel nonsense mutation in desmoplakin. Rev Esp Cardiol. 2011;64:530–534.

[14] Igual B, Zorio E, Maceira A, et al. Arrhythmogenic cardiomyopathy. Patterns of ventricular involvement using cardiac magnetic resonance. Rev Esp Cardiol. 2011;64:1114–1122.

[15] Goldstein S. The necessity of a uniform definition of sudden coronary death: witnessed death within 1 hour of the onset of acute symptoms. Am Heart J. 1982;103:156–159.

[16] Priori SG, Aliot E, Blomstrom LC, et al. Task force on sudden cardiac death of the European Society of Cardiology. Eur Heart J. 2001;22:1374–1450.

[17] Barriales-Villa R, Gimeno-Blanes JR, Zorio-Grima E, et al. Plan of action for inherited cardiovascular diseases: synthesis of recommendations and action algorithms. Rev Esp Cardiol. 2016;69:300–309.

[18] Charron P, Arad M, Arbustini E, et al. Genetic counselling and testing in cardiomyopathies: a position statement of the European Society of Cardiology Working Group on Myocardial and Pericardial Diseases. Eur Heart J. 2010;31:2715–2726.

[19] Pilichou K, Lazzarini E, Rigato I, et al. Large genomic rearrangements of desmosomal genes in Italian arrhythmogenic cardiomyopathy patients. Circ Arrhythm Electrophysiol. 2017;10:e005324. doi: 10.1161/CIRCEP.117.005324